Poor humoral and T-cell response to two-dose SARS-CoV-2 messenger RNA vaccine BNT162b2 in cardiothoracic transplant recipients.
René SchrammAngelika Costard-JäckleRasmus RiviniusBastian FischerBenjamin MüllerUdo BoekenAssad HaneyaZdenek ProvaznikCornelius KnabbeJan GummertPublished in: Clinical research in cardiology : official journal of the German Cardiac Society (2021)
The findings of poor immune responses to a two-dose BNT162b2 vaccination in cardiothoracic transplant patients have a significant impact for organ transplant recipients specifically and possibly for immunocompromised patients in general. It urges for a review of future vaccine strategies in these patients.